Introduction
Lamotrigine (LTG) is a popularly used antiepileptic drug (AED), but the use of LTG is limited because of cutaneous adverse drug reaction (cADR), although LTG commonly replaces other AEDs in clinical practice. [1] A number of studies have associated human leukocyte antigen (HLA) genotypes with an increased risk of cADR. A strong association between HLA-B*15:02 and carbamazepine (CBZ)-induced severe cADR, Stevens-Johnson syndrome, or toxic epidermal necrolysis (SJS/ TEN) has been identified in Han Chinese, [2] Thai, [3] Malay, [4] and Indian populations. [5] However, studies in Caucasian [6] and Japanese [7] populations did not show the same genetic expression, but showed an association with the HLA-A*31:01 allele instead. In Koreans, HLA-B*15:11 and HLA-A*31:01 were reported as genetic factors for CBZ-induced severe cutaneous adverse reactions (SCARs) including SJS. [8] The results suggest that the genetic factors in AED-induced cADRs would exhibit ethnic specificity due to the HLA allele frequencies in different populations. Due to the high cross-reactivity among aromatic AEDs such as phenytoin (PHT), CBZ, phenobarbital (PB), and LTG, [1] there have been a number of studies to identify risk HLA alleles for other aromatic AEDs based on the CBZ-induced cADR genetic biomarkers, HLA-B*1502 and HLA-A*3101. However, no association was found between LTG-induced cADR and the two HLA alleles in Koreans. [9, 10] The possible association of LTGinduced maculopapular eruption (MPE) and HLA alleles compared to LTG-tolerant patients were investigated in a Chinese population. [11] [12] Two previous studies investigated 21 MPE and 7 SJS/TEN patients, respectively. Therefore, the role of HLA alleles in LTG-induced cADR needs further investigation in the Korean population. In this study, we investigated the association of HLA-A, -B, and -C alleles in four patients with LTG-induced cADR in Korea.
Methods

Patients
We retrospectively reviewed the medical records of four patients who had LTG-induced cADR from 2010 to 2012 in Inje University Busan Paik Hospital, Busan, Korea. All patients were diagnosed with cADR by dermatology specialists. The causative drug was identified based on patient history. All of the patients took LTG for epilepsy. LTG-induced cADR was defined according to the following criteria: 1) occurrence within 12 weeks after first exposure to one of the implicated drugs; 2) manifestations of a cutaneous nature with a spotty, morbilliform, or maculopapular appearance; 3) exclusion of all other etiologies causing the cutaneous manifestations; and 4) amelioration of all cutaneous manifestations concurrent with withdrawal of the implicated drug. Our study was conducted with the approval of the Institutional Review Board of our hospital, and written informed consent was obtained from all patients.
HLA genotyping
Peripheral blood was collected from all four patients, and genomic DNA was extracted from peripheral blood mononuclear cells using a QIAamp Blood Mini Kit (QIAGEN, Hilden, Germany). We determined the HLA-A, -B, and -C genotypes using the PCR-SBT method (SBT Engine software version 2.20, GenDx, Utrecht, the Netherlands).
Results
All patients were of Korean ethnicity, and their age range was 26-69 years. Two patients were diagnosed with SJS, and the other two with MPE. The latency to skin rash after first exposure to LTG was 19 to 42 days, and the latency after maximum dose was 1-35 days. Two patients with MPE experienced cross-reactivity, one with phenytoin (PHT) and topiramate (TPM) (this patient had also experienced MPE due to LTG 7 years earlier), and another with CBZ about 20 days earlier ( Table 1 
Discussion
AED-induced cADR ranges from mild MPE to SCAR such as drug reaction with eosinophilia and systemic symptoms (DRESS), SJS, and TEN. [13] Particularly aromatic AEDs (PHT, PB, and CBZ) are known to be most frequently involved in cADR. [1, 14] Cross-reactivity among aromatic AEDs (PHT, CBZ, oxcarbazepine, PB, primidone, zonisamide, and LTG) is high (40-80%), which may be explained by the "hapten hypothesis" or "pharmacological interaction theory. " [1, 15] The LTG-induced cADR incidence rate was reported to be about 10%, with most showing mild rashes and 0.1-1% with severe rashes requiring hospitalization. [10] The mechanism of cADR HLA-A*24:02/B*51:01 and LTG-induced cADR 
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Transl Clin Pharmacol is unclear, but it has been thought to be immune-mediated hypersensitivity, especially in SCAR. Thus, there have been many studies regarding associations between HLA alleles and specific drug-related cADRs. [1] In this study, we performed HLA-A, -B, and -C genotyping in four patients with LTG-induced cADR, two with SJS and two with MPE, to identify whether there was an association between HLA alleles and the LTG-induced cADRs. The results suggest that Korean individuals with the HLA-A*24:02/B*51:01 haplotype may be susceptible to LTGinduced cADR; this haplotype was present in three of the four LTG-induced cADR patients (75%).
HLA-B*51:01 is a known positive marker for Behcet's disease (BD), [16] but none of the three patients with this allele was diagnosed with BD. BD is a chronic relapsing multisystem vasculitis involving oral, genital, ocular, and skin lesions. [17] The etiology of the disease is unknown, but it involves both innate and adaptive immune reactions. [16] The disease susceptibility gene involving the immune system may be affected in LTGinduced cADR. The two SJS patients had HLA-B*51:01 with HLA-C*14:02, which may be due to linkage disequilibrium (LD). A nonsignificant effect of HLA-C*14 in BD patients has been described, which may be due to a possibly significant LD between HLA-B*51 and C*14. [16] HLA-A*24:02 and B*51:01 frequencies in the Korean population are 21.65% and 8.35%, respectively. [18] The HLA-B*51:01 allele frequency in patients with CBZ-induced severe cADR was relatively lower than that in the general population in a Japanese study. [7] The HLA-A*24:02/B*59:01/C*01:02 haplotype was a high-risk genotype for LTG-induced severe cADR cases in the Japanese study. A protective effect of aromatic AED crossreactivity from HLA-A*24:02 was reported in a small Chinese study [19] , but not in a Norwegian study, which showed an association with LTG-induced rash. [20] A Korean study identified three risk factor alleles, HLA-A*24:02, C*01:02, and C*07:02, and two protective alleles, HLA-A*33:03 and C*07:01, for LTG-induced MPE. [10] Our patients had A*24:02 and C*07:02 but not C*01:02 as risk factors, and had A*33:03 among protective factors.
In our study, one patient with MPE from CBZ and LTG has a HLA*33:03 homozygous genotype (ID 2 in Tables 1-3) , which was reported to have a protective effect against LTG-induced MPE in both Korean and Chinese populations. [10, 11] The patient did not have HLA-B*15:02, B*15:11, B*31:01, and A*24:02, but she had HLA-B*58:01 as a homozygote; this allele was reported to be weakly associated with LTG-induced cADR in a population of European origin.
[21] The patient had both risk and protective genes, but MPE occurred with the two drugs without masking, which may be due to a stronger effect of the risk gene than of the protective one, or to the effect of an unknown gene and/or non-genetic factors. The other three patients, two with SJS and one with MPE, had HLA-A*24:02/B*51:01 alleles. In the HLA-A genotype, two among them have HLA-A*24:02/31:01, and one has HLA-A*24:02/24:02. Thus, all three patients had a known HLA-A allele pair in AED-induced cADR. The two SJS patients did not carry HLA-B*44:03, which was reported as a genetic risk factor for LTG-induced SJS/TEN in Koreans. [12] The MPE patient among these three showed cross-reactivity among aromatic and new AEDs, namely PHT and TPM, as well as LTG. He experienced MPE again when rechallenged with LTG. In these patients, there could be additional factors or independent genetic factors that induce cADR. Some reported risk factors for LTG-induced cADR are rapid titration, concomitant use of valproic acid, prior history of anticonvulsant-associated rash, female gender, and age less than 13 years. [22] In our study, the patients also had other factors mentioned above as risk factors in addition to genetic predisposition.
The limitations of this study included a very small number of LTG-induced cADR patients, only four including two SJS and two MPE patients, and no LTG-tolerant patient data. The other limitation was that the study focused only on HLA class I genotypes and did not include class II genotypes. However, three of the four patients (75%) had the same alleles in HLA-A and -B, which will be valuable information for future investigation of the possibility of a factor predicting or affecting LTG-induced cADR, including SJS and MPE. Prevention of cADR is very important in drug therapy for patients.
In conclusion, we found that LTG-induced cADRs can occur Eun-Young Kim, et al. 
